Smartcatch
Portola Valley, US · Delaware corporation · 1 known investors
SmartCatch develops compact microfiltration devices that isolate Circulating Tumor Cells (CTCs) directly from whole blood without pre-analytical steps, enabling liquid biopsy for cancer diagnosis and monitoring. Its products target clinicians, pharmaceutical companies, and researchers in medical oncology and precision medicine.
Founders & leadership
MD
MARK DAHMExecutive
Board
RD
RICHARD DEATLEYBoard director
RT
ROBERT TERRYBoard director
TD
TJ DURNANBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$575.6K disclosed across 1 round · 2017
▶$575.6KraisedMar 2017 · 3 investors · Other TechnologyRule 506(b)
▶$575.6KraisedMar 2017 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- RICHARD DEATLEYDirector
- ROBERT TERRYDirector
- TJ DURNANDirector
- MARK DAHMExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $575.6K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Smartcatch do?
- SmartCatch develops compact microfiltration devices that isolate Circulating Tumor Cells (CTCs) directly from whole blood without pre-analytical steps, enabling liquid biopsy for cancer diagnosis and monitoring. Its products target clinicians, pharmaceutical companies, and researchers in medical oncology and precision medicine.
- Who are Smartcatch's investors?
- Smartcatch's investors include Kurma Partners.
- How much funding has Smartcatch raised?
- Smartcatch has disclosed $575.6K raised across 1 round.
- Where is Smartcatch headquartered?
- Smartcatch is headquartered in Portola Valley, US.